Predictive model to identify patients requiring extended interferon therapy in chronic hepatitis B

Table 1 Comparison of predictors for PEGylated interferon treatment response in chronic hepatitis B between the study by Yan et al[2] and 37 similar studies published from 2021 to 2025

Category	Predictors	n1	Ref.
Hepatitis B markers	HBsAg	20	[1,2,6,9,10,12,14,17-21,25,27,30,31,35,36,38,39]
	HBeAg	2	[1,13]
	Anti-HBs	2	[13,29]
	Anti-HBc	1	[17]
Biomarkers	Immunoglobulins	1	[4]
	Lipid	1	[15]
	Ferritin	1	[26]
	ALT	5	[27,30,31,36,39]
Patient characteristics	Cirrhosis	2	[2,21]
	Fatty liver	1	[12]
	Gender	1	[21]
	Age	3	[27,30,31]
mRNA	TRIM19/38	1	[8]
	LY6E/TRIM6	1	[23]
Immune-related markers	sPD-1/sPD-L1	1	[11]

¹The number includes the study of Yan et al[2].

TRIM19/38: Triple motif protein 19/38 mRNA; LY6E: Lymphocyte antigen 6 family member E; TRIM6: Triple motif protein 6; sPD-1: Soluble programmed cell death-1; sPD-L1: Soluble programmed cell death ligand-1; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; anti-HBs: Anti-hepatitis B surface antibody; anti-HBc: Hepatitis B core antibody; ALT: Alanine aminotransferase.

Table 2 Number of related studies published each year

Publication year	2021	2022	2023	2024	2025
n1	1	3	2	10	22
Ref.	[3]	[4-6]	[7,8]	[9-18]	[2,19-39]

¹The number includes the study of Yan et al[2].

Table 3 Locations of relevant studies

Study subject	Chinese	Taiwanese	Koreans	White men	Other ethnics
n1	371	0	1	0	0
Ref.	[2-15,17-39]		[16]

¹The number includes the study of Yan et al[2].